gemfibrozil

Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).

Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil, is a potent and competitive inhibitor of P450 (CYP) isoform CYP2C8, with an IC50 of 4.07 μM.

Gemfibrozil-D6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil (T1415) is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (T1415) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

Gemfibrozil-D6 (Standard) is a reference standard of Gemfibrozil-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Gemfibrozil-d6 is used as an internal standard when quantitatively analyzing Gemfibrozil by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry. Gemfibrozil is a peroxidase activator α and peroxidase activation receptor γ agonist.

Gemfibrozil (Standard) is the standard substance of Gemfibrozil, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).

AH057 is a novel JAK inhibitor, effectively blocking the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and leading to compromised cell proliferation and invasion, increasing apoptosis, arrested cell cycles, and impairing tumor progression in vitro and in vivo

Melinamide is an antilipidemic compound with pharmacological properties similar to gemfibrozil. Melinamide reduces elevated serum lipids primarily by lowering the triglyceride-rich very low-density lipoprotein (VLDL) fraction. In Type III hyperlipoproteinemia, where cholesterol elevation arises from intermediate-density lipoproteins (IDL), melinamide can decrease serum cholesterol levels.